Stock Research for IMMY

IMMY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IMMY Stock Chart & Research Data

The IMMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IMMY Due diligence Resources & Stock Charts

The IMMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IMMY Detailed Price Forecast - CNN Money CNN View IMMY Detailed Summary - Google Finance
Yahoo View IMMY Detailed Summary - Yahoo! Finance Zacks View IMMY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IMMY Trends & Analysis - Trade-Ideas Barrons View IMMY Major Holders - Barrons
NASDAQ View IMMY Call Transcripts - NASDAQ Seeking View IMMY Breaking News & Analysis - Seeking Alpha
Spotlight View IMMY Annual Report - CompanySpotlight.com OTC Report View IMMY OTC Short Report - OTCShortReport.com
TradeKing View IMMY Fundamentals - TradeKing Charts View IMMY SEC Filings - Bar Chart
WSJ View Historical Prices for IMMY - The WSJ Morningstar View Performance/Total Return for IMMY - Morningstar
MarketWatch View the Analyst Estimates for IMMY - MarketWatch CNBC View the Earnings History for IMMY - CNBC
StockMarketWatch View the IMMY Earnings - StockMarketWatch MacroAxis View IMMY Buy or Sell Recommendations - MacroAxis
Bullish View the IMMY Bullish Patterns - American Bulls Short Pains View IMMY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IMMY Stock Mentions - StockTwits PennyStocks View IMMY Stock Mentions - PennyStockTweets
Twitter View IMMY Stock Mentions - Twitter Invest Hub View IMMY Investment Forum News - Investor Hub
Yahoo View IMMY Stock Mentions - Yahoo! Message Board Seeking Alpha View IMMY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IMMY - SECform4.com Insider Cow View Insider Transactions for IMMY - Insider Cow
CNBC View IMMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IMMY - OTC Markets
Yahoo View Insider Transactions for IMMY - Yahoo! Finance NASDAQ View Institutional Holdings for IMMY - NASDAQ


Stock Charts

FinViz View IMMY Stock Insight & Charts - FinViz.com StockCharts View IMMY Investment Charts - StockCharts.com
BarChart View IMMY Stock Overview & Charts - BarChart Trading View View IMMY User Generated Charts - Trading View




Latest Financial News for IMMY


Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018
Posted on Wednesday July 18, 2018

SAN DIEGO , July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...


ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery
Posted on Wednesday May 30, 2018

SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion.  The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure.  The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery.  The control group of 249 eyes received a standard topical regimen postoperatively.


Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine
Posted on Tuesday May 29, 2018

LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.


Imprimis: 1Q Earnings Snapshot
Posted on Tuesday May 15, 2018

The San Diego-based company said it had a loss of 17 cents per share. The pharmaceutical and drug compounding company posted revenue of $8.9 million in the period. In the final minutes of trading on Tuesday, ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.